Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 438 results for cardiovascular disease

  1. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  2. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

  3. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  4. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline has been updated and replaced by NICE guideline NG238.

  5. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death (HTG460)

    Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. This involves placing a device under the skin of the chest, which detects and treats fast heartbeats called tachyarrhythmias.

  6. Targeted-release budesonide for treating primary IgA nephropathy (TA1128)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

  7. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  8. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  9. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

  10. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  11. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  12. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

  13. Pulsed-field ablation for atrial fibrillation (HTG755)

    Evidence-based recommendations on pulsed-field ablation for atrial fibrillation. This involves using electric field energy to destroy heart cells that are transmitting abnormal electrical impulses.

  14. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  15. Stage 4: treatment, assessment and monitoring

    In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.